Searched for
ORIGINAL VIALS
Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...- After Gurgaon’s Rs 70 lakh fake Mounjaro seizure, more stocks found in Hyderabad; Racket may span multiple statesThe investigation into fake Mounjaro injections has widened beyond NCR after authorities confirmed that part of the seized batch was sent t...
- What’s powering Mounjaro’s rise to the top of Indian drug marketMounjaro has made a splash in Indian healthcare, emerging as the go-to solution for both diabetes management and weight loss. This remarkab...
- Jubilant Pharmova arm to invest $300 mn in US by FY28 to double sterile injectable capacityJubilant HollisterStier LLC is investing USD 300 million by FY28 to double its sterile injectable manufacturing capacity in the US. The com...
- Supreme Court asks Zydus Lifesciences to approach Delhi HC over ban on selling breast cancer drug SigrimaThe Supreme Court has instructed Zydus Lifesciences to approach the Delhi High Court. Zydus is seeking relief from an order that prevents t...
- Delhi HC allows Zydus Lifesciences to sell breast cancer drug SigrimaThe Delhi High Court division bench has allowed Zydus Lifesciences to sell its breast cancer drug Sigrima amidst accusations of it being si...
- 200-year-old message in a bottle left by archaeologist unearthed in FranceVolunteers have discovered a 200-year-old message in a bottle at an excavation site in Normandy, France. The letter, left by archaeologist ...
- Delhi HC asks Centre to hold meeting with Roche to ensure immediate supply of TocilizumabJustice Prathiba M Singh said the officials of the ministry and the department shall hold a meeting with representatives of Roche India and...
- FDA authorises 2 changes to Moderna's vaccineThe agency said late on Thursday that it approved new vials from Moderna that can contain up to 15 doses each, compared with the original v...
- Biocon defends limited trial patients for Itolizumab nod, says followed science of "highest order"The company is marketing the drug as a replacement to Roche Pharma’s Tocilizumab (originally approved for rheumatoid arthritis) that is cur...
- Biocon to take on Roche Pharma with its psoriasis drug to treat moderate to severe Covid patientsThe company is marketing the drug as a replacement to Roche’s tocilizumab (originally approved for rheumatoid arthritis) that is currently ...
- BMC to acquire 20,000 doses of Tocilizumab even as trials yet to determine efficacyThe health ministry has also recommended tocilizumab in its national clinical guidelines, which say the drug may be considered for patients...
- Biocon shares gains on cancer drug launchA biosimilar is a near copy of an original complex biologic drug.
- Beer on the Moon may soon be a realityScientists of Indian-origin are trying to brew beer in a canister sent to the Moon aboard a lunar vehicle.
- Biosimilar drugs are priced too high and do little to improve accessibility: DoctorsBiosimilar drugs are follow-on biologics that have nearly the same efficacy as the original drug and used to treat cancer or autoimmune dis...
- Hetero launches biosimilar Rituximab in IndiaHyderabad based Hetero pharma has launched biosimilar drug Rituximab under the brand name of MABALL, used in the treatment of blood cancer.
- Biocon launches breast-cancer drug CANMAbPriced at Rs 19,500 per vial, Biocon is expecting to target close to 35,000 patients with this drug.
- Barcode procedures for pharma companies simplifiedIn a move to simplify barcode procedures for pharma cos, the govt has decided to treat mono cartons containing medicines also as primary le...
- Panacea Biotec to launch breast cancer drugPanacea Biotec will soon launch a generic version of Abraxis Bioscience's breast cancer medicine Abraxane at half the price of the original...
- Natco Pharma faces criminal actionThe country’s top drug regulator plans to initiate criminal proceedings against Hyderabad-based Natco Pharma for selling “substandard” brea...
Load More
